Obesity and children with special healthcare needs: special considerations for a special population

Purni Abeysekara1, Renee Turchi, Margaret O'Neil

  • 1aDrexel School of Public Health bDrexel College of Nursing and Health Professions, Drexel University cDepartment of Pediatrics, St. Christopher's Hospital for Children, Philadelphia, Pennsylvania, USA.

Insights

Childhood obesity is a persistent issue, particularly for children and youth with special healthcare needs (CYSHCN). This review offers pediatric providers guidance on managing obesity in CYSHCN through assessment, treatment, and interdisciplinary collaboration.

Area of Science:

  • Pediatric Health
  • Obesity Management
  • Special Healthcare Needs

Background:

  • Childhood obesity remains a significant public health concern.
  • Children and youth with special healthcare needs (CYSHCN) face a higher prevalence of obesity.
  • Existing frameworks like ICF and AAP recommendations support interventions for physical activity and healthy eating in CYSHCN.

Purpose of the Study:

  • To provide pediatric providers with evidence-based recommendations for the assessment, treatment, and management of obesity in CYSHCN.
  • To highlight the importance of tailored strategies for this vulnerable population.
  • To leverage established models for promoting healthy lifestyles.

Main Methods:

  • This review synthesizes current literature and expert recommendations.
  • It focuses on factors influencing physical activity and healthy eating in CYSHCN.
  • The review emphasizes a collaborative, interdisciplinary approach.

Main Results:

  • Personal, environmental, and parental factors significantly impact participation in physical activity and healthy eating among CYSHCN.
  • Physical activity is achievable for CYSHCN with appropriate guidance and supervision.
  • Parental guidance is crucial for helping CYSHCN with dietary restrictions make healthier food choices.
  • Creative strategies are essential for promoting healthy behaviors in this population.

Conclusions:

  • Addressing obesity and promoting healthy behaviors can improve health outcomes and quality of life for CYSHCN.
  • Pediatricians should collaborate with families and interdisciplinary teams to assess obesity risks.
  • Providing CYSHCN with necessary skills and resources is vital for obesity prevention and management.
Abstract

Related Concept Videos

Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.5K
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
364
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
437
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
324
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
954
Bulimia Nervosa01:30

Bulimia Nervosa

Bulimia nervosa is a complex and severe eating disorder characterized by a cyclical pattern of binge-and-purge eating pattern. It generally involves an episode of binge eating, followed by compensatory behaviors such as vomiting, excessive exercise, laxative use, or fasting, to prevent weight gain. Despite often maintaining a normal weight, individuals with bulimia are intensely preoccupied with their body image and harbor an overwhelming fear of gaining weight. This can contribute to the...
1.1K